| 2023-07-05 |
Vertex Pharmaceuticals Incorporated |
European Commission Approves ORKAMBI® (lumacaftor/ivacaftor) for the Treatment of Children With Cystic Fibrosis Ages 1 to <2 Years Old vrtx.com ↗ |
| 2023-04-27 |
Vertex Pharmaceuticals Incorporated |
Vertex Receives CHMP Positive Opinion for ORKAMBI® (lumacaftor/ivacaftor) in Children With Cystic Fibrosis Ages 1 to <2 Years Old vrtx.com ↗ |
| 2022-09-02 |
Vertex Pharmaceuticals Incorporated |
Vertex Announces U.S. FDA Approval for ORKAMBI® (lumacaftor/ivacaftor) in Children With Cystic Fibrosis Ages 12 to <24 months vrtx.com ↗ |
| 2021-06-25 |
Vertex Pharmaceuticals Incorporated |
Vertex Announces New Portfolio Reimbursement Agreement in Italy Including KAFTRIO®, SYMKEVI® and Additional Indications of ORKAMBI® and KALYDECO® for Eligible Patients With Cystic Fibrosis vrtx.com ↗ |
| 2020-04-21 |
Vertex Pharmaceuticals Incorporated |
Vertex Announces Innovative Reimbursement Agreement in Switzerland for ORKAMBI® (lumacaftor/ivacaftor) and SYMDEKO® (tezacaftor/ivacaftor and ivacaftor) for Eligible Cystic Fibrosis Patients vrtx.com ↗ |
| 2019-11-20 |
Vertex Pharmaceuticals Incorporated |
French Authorities Approve National Reimbursement of ORKAMBI® (lumacaftor/ivacaftor) for Eligible People Ages Two and Older With Cystic Fibrosis vrtx.com ↗ |
| 2019-10-21 |
Vertex Pharmaceuticals Incorporated |
Spanish Government Approves National Reimbursement of ORKAMBI® (lumacaftor/ivacaftor) and SYMKEVI® (tezacaftor/ivacaftor) in Combination With KALYDECO® (ivacaftor) vrtx.com ↗ |
| 2019-10-19 |
Vertex Pharmaceuticals Incorporated |
Vertex Announces Reimbursement of Cystic Fibrosis Medicines SYMDEKO® (tezacaftor/ivacaftor and ivacaftor) for Eligible Patients Ages 12 and Older, and ORKAMBI® (lumacaftor/ivacaftor) in Children Ages 2 to 5, With Certain CFTR Mutations in Australia vrtx.com ↗ |
| 2019-09-12 |
Vertex Pharmaceuticals Incorporated |
Vertex Announces New Access Agreement with Scottish Government for ORKAMBI® (lumacaftor/ivacaftor) and SYMKEVI® (tezacaftor/ivacaftor) vrtx.com ↗ |
| 2019-01-21 |
Vertex Pharmaceuticals Incorporated |
Vertex Announces European Commission Approval for ORKAMBI® (lumacaftor/ivacaftor) for Treatment of Children with Cystic Fibrosis Aged 2 to 5 Years Old with Most Common Form of the Disease vrtx.com ↗ |
| 2018-12-19 |
Vertex Pharmaceuticals Incorporated |
Vertex Announces it will Submit Cystic Fibrosis Medicines ORKAMBI® (lumacaftor/ivacaftor) as well as SYMKEVI® (tezacaftor/ivacaftor) to be Used in Combination with ivacaftor, to the Scottish Medicines Consortium for Appraisal vrtx.com ↗ |
| 2018-12-13 |
Vertex Pharmaceuticals Incorporated |
Health Canada Grants Market Authorization for ORKAMBI® (lumacaftor/ivacaftor) for Children with Cystic Fibrosis Aged 2 to 5 Years Old with Most Common Form of the Disease vrtx.com ↗ |
| 2018-11-16 |
Vertex Pharmaceuticals Incorporated |
Vertex Receives European CHMP Positive Opinion for ORKAMBI® (lumacaftor/ivacaftor) for Treatment of Children with Cystic Fibrosis Aged 2 to 5 Years Old with Most Common Form of the Disease vrtx.com ↗ |
| 2018-09-03 |
Vertex Pharmaceuticals Incorporated |
Vertex Announces Reimbursement Agreement in Australia for ORKAMBI® (lumacaftor/ivacaftor) for People with Cystic Fibrosis Ages Six Years and Older with Two Copies of the F508del Mutation vrtx.com ↗ |
| 2018-08-20 |
Vertex Pharmaceuticals Incorporated |
Vertex Receives a Positive PBAC Recommendation for Reimbursement of ORKAMBI® (lumacaftor/ivacaftor) to Treat Australians Ages Six and Over with Cystic Fibrosis and Two Copies of the F508del Mutation vrtx.com ↗ |
| 2018-08-07 |
Vertex Pharmaceuticals Incorporated |
FDA Approves ORKAMBI® (lumacaftor/ivacaftor) as First Medicine to Treat the Underlying Cause of Cystic Fibrosis for Children Ages 2-5 Years with Most Common Form of the Disease vrtx.com ↗ |
| 2018-06-18 |
Vertex Pharmaceuticals Incorporated |
Vertex Announces Long-Term Access Agreement in Sweden for Cystic Fibrosis Medicine ORKAMBI® (lumacaftor/ivacaftor) vrtx.com ↗ |
| 2018-01-10 |
Vertex Pharmaceuticals Incorporated |
Vertex Receives EU Approval for ORKAMBI® (lumacaftor/ivacaftor) in Children with Cystic Fibrosis Ages 6-11 with Two Copies of the F508del Mutation vrtx.com ↗ |
| 2017-11-10 |
Vertex Pharmaceuticals Incorporated |
Vertex Receives CHMP Positive Opinion for ORKAMBI® (lumacaftor/ivacaftor) for the Treatment of Children with Cystic Fibrosis Ages 6-11 with Two Copies of the F508del Mutation in the European Union vrtx.com ↗ |
| 2017-07-13 |
Vertex Pharmaceuticals Incorporated |
Vertex Announces Reimbursement Agreement in Italy for ORKAMBI® (Lumacaftor/Ivacaftor), the First Medicine to Treat the Underlying Cause of Cystic Fibrosis in People Ages 12 and Older with Two Copies of the F508del Mutation vrtx.com ↗ |
| 2017-06-09 |
Vertex Pharmaceuticals Incorporated |
Vertex Announces Nine Presentations of Data on ORKAMBI® (lumacaftor/ivacaftor) and KALYDECO® (ivacaftor) at the European Cystic Fibrosis Society (ECFS) Conference vrtx.com ↗ |
| 2017-06-01 |
Vertex Pharmaceuticals Incorporated |
Vertex Announces Long-Term Reimbursement Agreement with the Republic of Ireland for ORKAMBI® (lumacaftor/ivacaftor), KALYDECO® (ivacaftor) and Future Cystic Fibrosis Medicines vrtx.com ↗ |
| 2016-12-19 |
Vertex Pharmaceuticals Incorporated |
Vertex Announces German Reimbursement Agreement for ORKAMBI® (Lumacaftor/Ivacaftor), the First Medicine to Treat the Underlying Cause of Cystic Fibrosis in People Ages 12 and Older with Two Copies of the F508del Mutation vrtx.com ↗ |
| 2016-11-07 |
Vertex Pharmaceuticals Incorporated |
Positive Phase 3 Study of ORKAMBI® in Children With Cystic Fibrosis Ages 6-11 Who Have Two Copies of the F508del Mutation Supports a Submission to the European Medicines Agency in the First Half of 2017 vrtx.com ↗ |
| 2016-10-27 |
Vertex Pharmaceuticals Incorporated |
Vertex Presents Long-Term Data Demonstrating that ORKAMBI® (lumacaftor/ivacaftor) and KALYDECO® (ivacaftor) Show the Potential to Modify the Progression of CF vrtx.com ↗ |
| 2016-09-28 |
Vertex Pharmaceuticals Incorporated |
U.S. Food and Drug Administration Approves ORKAMBI® (lumacaftor/ivacaftor) for Use in Children with Cystic Fibrosis Ages 6 through 11 who have Two Copies of the F508del Mutation vrtx.com ↗ |
| 2016-06-10 |
Vertex Pharmaceuticals Incorporated |
Vertex Announces Presentations of Data for KALYDECO® (ivacaftor) and ORKAMBI® (lumacaftor/ivacaftor) at European Cystic Fibrosis Society (ECFS) Conference vrtx.com ↗ |
| 2016-05-31 |
Vertex Pharmaceuticals Incorporated |
U.S. FDA Accepts for Priority Review Supplemental New Drug Application for the Use of ORKAMBI® (lumacaftor/ivacaftor) in Children with Cystic Fibrosis Ages 6 to 11 who have Two Copies of the F508del Mutation vrtx.com ↗ |
| 2016-03-08 |
Vertex Pharmaceuticals Incorporated |
Vertex Receives Australian Approval for ORKAMBI® (lumacaftor/ivacaftor), the First Medicine to Treat the Underlying Cause of Cystic Fibrosis in People Ages 12 and Older with Two Copies of the F508del Mutation vrtx.com ↗ |
| 2015-11-20 |
Vertex Pharmaceuticals Incorporated |
Vertex Receives EU Approval for ORKAMBI® (lumacaftor/ivacaftor), the First Medicine to Treat the Underlying Cause of Cystic Fibrosis in People Ages 12 and Older with Two Copies of the F508del Mutation vrtx.com ↗ |
| 2015-09-25 |
Vertex Pharmaceuticals Incorporated |
Vertex Receives CHMP Positive Opinions for ORKAMBI™ (lumacaftor/ivacaftor) and KALYDECO® (ivacaftor) in the European Union vrtx.com ↗ |
| 2015-07-02 |
Vertex Pharmaceuticals Incorporated |
FDA Approves ORKAMBI™ (lumacaftor/ivacaftor) - the First Medicine to Treat the Underlying Cause of Cystic Fibrosis for People Ages 12 and Older with Two Copies of the F508del Mutation vrtx.com ↗ |
| 2015-07-02 |
Vertex Pharmaceuticals Incorporated |
ADDING MULTIMEDIA FDA Approves ORKAMBI™ (lumacaftor/ivacaftor) - the First Medicine to Treat the Underlying Cause of Cystic Fibrosis for People Ages 12 and Older with Two Copies of the F508del Mutation vrtx.com ↗ |
| 2015-05-12 |
Vertex Pharmaceuticals Incorporated |
Food and Drug Administration Advisory Panel Voted 12 to 1 to Recommend Approval of ORKAMBI™ (lumacaftor/ivacaftor) to Treat People with Cystic Fibrosis Ages 12 and Older Who Have Two Copies of the F508del Mutation vrtx.com ↗ |
|